An analysis of the economic impact of biosimilars in oncology and hematology found that biosimilars for rituximab (Rituxan) and trastuzumab (Herceptin) offer economic benefit compared with their reference drugs as first-line treatment in follicular lymphoma and as neoadjuvant breast cancer treatment, respectively, explained Jacopo Giuliani, MD.
[There are] potentially different monoclonal antibodies and granulocyte [colony stimulating] factors.
Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019;39(7):3971-3973. doi: 10.21873/anticanres.13552.
... to read the full story